Boan Biotech Out-licenses Its Dulaglutide Injection in the U.S.

Yantai, June 4, 2026 -- Boan Biotech announced that it has entered into a licensing agreement for the United States rights of BA5101 (Dulaglutide Injection). Under the agreement, the partner will comm...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026

Boan Biotech Presents Updated Phase I Clinical Data for BA1301 (Anti-CLDN18.2 ADC) at the 2026 ASCO Annual Meeting

Yantai, China, May 30, 2026 -- Boan Biotech today presented the updated data of a Phase I clinical trial for its BA1301, an investigational antibody-drug conjugate (ADC) targeting CLDN18.2, at the 202...

Boan Biotech Submits a Biologics License Application for Two Denosumab Biosimilars in the U.S.

Boan Biotech announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its two biosimilars: BA6101 (denosumab injection 60 mg) and ...

VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.

FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 22 JUNE 2026 (APPLICABLE TO HOLDERS OF H SHARES)

NOTICE OF ANNUAL GENERAL MEETING

(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS (7) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES (8) GEN

Boan Biotech’s Boluojia® Newly Approved in China for Treating Bone Metastases from Solid Tumors and Multiple Myeloma

Boan Biotech announced today that China’s National Medical Products Administration (NMPA) has approved the supplemental application for Boluojia® (denosumab injection 120 mg) for the treatment o...

VOLUNTARY ANNOUNCEMENT BOLUOJIA (DENOSUMAB INJECTION) NEWLY APPROVED IN CHINA FOR TREATING BONE METASTASES FROM SOLID TUMORS AND MULTIPLE MYELOMA